BioCentury
ARTICLE | Clinical News

Triapine: Phase I

March 6, 2000 8:00 AM UTC

In a single dose U.S. Phase I study, Triapine was well tolerated at each of nine dose levels when given intravenously as a 2-hour infusion every 4 weeks. At the highest dose level, no significant toxi...